177 related articles for article (PubMed ID: 12137406)
21. Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.
Corbett AH; Kashuba AD
Curr Opin Investig Drugs; 2002 Mar; 3(3):384-90. PubMed ID: 12054084
[TBL] [Abstract][Full Text] [Related]
22. Nuvion. Protein Design Labs.
Trajkovic V
Curr Opin Investig Drugs; 2002 Mar; 3(3):411-4. PubMed ID: 12054088
[TBL] [Abstract][Full Text] [Related]
23. GL-701 Genelabs.
Norman P
Curr Opin Investig Drugs; 2001 Feb; 2(2):231-6. PubMed ID: 11816836
[TBL] [Abstract][Full Text] [Related]
24. Oral heparin (Emisphere).
Dunn A
IDrugs; 2000 Jul; 3(7):817-24. PubMed ID: 16080057
[TBL] [Abstract][Full Text] [Related]
25. Repinotan Bayer.
Lutsep HL
Curr Opin Investig Drugs; 2002 Jun; 3(6):924-7. PubMed ID: 12137415
[TBL] [Abstract][Full Text] [Related]
26. Exubera. Inhale therapeutic systems.
Bindra S; Cefalu WT
Curr Opin Investig Drugs; 2002 May; 3(5):758-62. PubMed ID: 12090549
[TBL] [Abstract][Full Text] [Related]
27. Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from prospective, randomized, clinical trials of percutaneous coronary intervention and coronary artery bypass graft surgery.
Morrison DA; Sacks J
Minerva Cardioangiol; 2003 Oct; 51(5):585-97. PubMed ID: 14551526
[TBL] [Abstract][Full Text] [Related]
28. SR-90107 (Sanofi-Synthélabo).
Liu F; Bagley WP; Carroll RC
IDrugs; 2000 Sep; 3(9):1088-99. PubMed ID: 16049869
[TBL] [Abstract][Full Text] [Related]
29. Oprelvekin. Genetics Institute.
Sitaraman SV; Gewirtz AT
Curr Opin Investig Drugs; 2001 Oct; 2(10):1395-400. PubMed ID: 11890354
[TBL] [Abstract][Full Text] [Related]
30. (S)-Zopiclone Sepracor.
Georgiev V
Curr Opin Investig Drugs; 2001 Feb; 2(2):271-3. PubMed ID: 11816843
[TBL] [Abstract][Full Text] [Related]
31. Treprostinil sodium Pharmacia.
Chattaraj SC
Curr Opin Investig Drugs; 2002 Apr; 3(4):582-6. PubMed ID: 12090728
[TBL] [Abstract][Full Text] [Related]
32. CCI-779 Wyeth.
Elit L
Curr Opin Investig Drugs; 2002 Aug; 3(8):1249-53. PubMed ID: 12211424
[TBL] [Abstract][Full Text] [Related]
33. Deramciclane (Egis).
Kõks S; Vasar E
Curr Opin Investig Drugs; 2002 Feb; 3(2):289-94. PubMed ID: 12020062
[TBL] [Abstract][Full Text] [Related]
34. Transgenic antithrombin III (Genzyme).
Yeung PK
IDrugs; 2000 Jun; 3(6):669-73. PubMed ID: 16096931
[TBL] [Abstract][Full Text] [Related]
35. Abetimus (La Jolla pharmaceuticals).
Lorenz HM
Curr Opin Investig Drugs; 2002 Feb; 3(2):234-9. PubMed ID: 12020052
[TBL] [Abstract][Full Text] [Related]
36. DP-VPA D-Pharm.
Labiner DM
Curr Opin Investig Drugs; 2002 Jun; 3(6):921-3. PubMed ID: 12137414
[TBL] [Abstract][Full Text] [Related]
37. Tomoxetine (Eli Lilly & Co).
Preti A
Curr Opin Investig Drugs; 2002 Feb; 3(2):272-7. PubMed ID: 12020059
[TBL] [Abstract][Full Text] [Related]
38. Iloperidone (Novartis).
Hesselink JM
IDrugs; 2002 Jan; 5(1):84-90. PubMed ID: 12861482
[TBL] [Abstract][Full Text] [Related]
39. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Mahaffey KW; Granger CB; Nicolau JC; Ruzyllo W; Weaver WD; Theroux P; Hochman JS; Filloon TG; Mojcik CF; Todaro TG; Armstrong PW;
Circulation; 2003 Sep; 108(10):1176-83. PubMed ID: 12925455
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
Théroux P; Armstrong PW; Mahaffey KW; Hochman JS; Malloy KJ; Rollins S; Nicolau JC; Lavoie J; Luong TM; Burchenal J; Granger CB
Eur Heart J; 2005 Oct; 26(19):1964-70. PubMed ID: 15872036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
